Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04517149
Recruitment Status : Recruiting
First Posted : August 18, 2020
Last Update Posted : June 15, 2021
Sponsor:
Information provided by (Responsible Party):
4D Molecular Therapeutics

Brief Summary:
This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in retinitis pigmentosa GTPase regulator (RPGR).

Condition or disease Intervention/treatment Phase
X-Linked Retinitis Pigmentosa Biological: 4D-125 IVT Injection Other: Observational Phase 1 Phase 2

Detailed Description:

This Phase 1/2 study will gather data in an observational phase Natural History Cohort to further characterize and evaluate natural disease progression in male patients with genetically-confirmed X-linked retinitis pigmentosa (XLRP) caused by mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR). The study will also evaluate the safety and tolerability, as assessed by frequency and severity of ocular and systemic adverse events, as well as preliminary clinical efficacy of a single intravitreal (IVT) injection of 4D-125 at two dose levels in this patient population.

4D-125 has been developed as a gene replacement therapy for XLRP. After receiving 4D-125, patients will be followed for 24 months with continued safety follow-up. Secondary endpoints will assess preliminary efficacy measures at 12 months after 4D-125 administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: In Phase 1, up to 2 dose exploration cohorts will be enrolled; each cohort will initially recruit up to 3 patients to receive a single uniocular IVT injection of 4D-125 in a standard 3+3 design. The cohort will be expanded in the event of a dose limiting toxicity (DLT). Any cohort may be expanded by an additional 3 subjects (to a maximum of 9 patients) to provide additional safety information and/or to confirm the selected dose for expansion. Once the dose level has been selected, the Phase 2 Dose Expansion Cohort will be opened to dose an additional 6-12 patients.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Actual Study Start Date : June 9, 2020
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 4D-125 Dose Exploration

Dose 1 and Dose 2

4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1.

Biological: 4D-125 IVT Injection
4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.

Experimental: 4D-125 Dose Expansion
4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1.
Biological: 4D-125 IVT Injection
4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.

Observational
Natural History
Other: Observational
Natural History




Primary Outcome Measures :
  1. Primary outcome measure [ Time Frame: 24 months ]
    Incidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parameters



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Natural History Key Inclusion Criteria:

  • Male, ≥ 6 years of age at the time of informed consent
  • Hemizygous non-syndromic RPGR mutation confirmed by genetic testing

Interventional Key Inclusion Criteria:

  • Male, ≥18 years of age
  • Hemizygous non-syndromic RPGR mutation confirmed by genetic testing
  • Phase 1 Dose Exploration: At least one eye amenable to IVT injection and BCVA ≤ 78 ETDRS letters (~20/32) and ≥ 34 ETDRS letters (~20/200)
  • Phase 2 Dose Expansion: At least one eye amenable to IVT injection AND both eyes must have BCVA ≥ 34 ETDRS letters (~20/200)

Key Exclusion Criteria (all cohorts)

  • Patient has previously received any AAV treatment
  • Pre-existing eye conditions or surgical complications that would preclude participation in an interventional clinical trial or interfere with the interpretation of study endpoints

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04517149


Contacts
Layout table for location contacts
Contact: Olivia Lam 510-902-2065 clinicaltrials@4DMT.com

Locations
Layout table for location information
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Mary Preston       Mary.Preston@cuanschutz.edu   
Principal Investigator: Marc Mathias, MD         
United States, Michigan
University of Michigan Kellogg Eye Center Recruiting
Ann Arbor, Michigan, United States, 48105
Contact: Stephanie Wietholter       scwoo@med.umich.edu   
Principal Investigator: Cagri Besirli, MD, PhD         
United States, North Carolina
Duke University Eye Center/Dept. of Ophthalmology Recruiting
Durham, North Carolina, United States, 27710
Contact: Carol White, CCRC       Carol.White302@duke.edu   
Principal Investigator: Alessandro Iannaccone, MD         
United States, Oregon
Casey Eye Institute, Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Sabrina Pol       Pol@ohsu.edu   
Principal Investigator: Paul Yang, MD, PhD         
United States, Texas
Retina Foundation of the Southwest Recruiting
Dallas, Texas, United States, 75231
Contact: Martin Klein       MKlein@retinafoundation.org   
Principal Investigator: David Birch, PhD         
United States, Utah
University of Utah John A. Moran Eye Center Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Susan Allman       Susan.Allman@hsc.utah.edu   
Principal Investigator: Paul Bernstein, MD, PhD         
Sponsors and Collaborators
4D Molecular Therapeutics
Investigators
Layout table for investigator information
Study Director: Robert Kim, MD 4D Molecular Therapeutics
Layout table for additonal information
Responsible Party: 4D Molecular Therapeutics
ClinicalTrials.gov Identifier: NCT04517149    
Other Study ID Numbers: 4D-125-C001
First Posted: August 18, 2020    Key Record Dates
Last Update Posted: June 15, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by 4D Molecular Therapeutics:
XLRP
Gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinitis
Retinitis Pigmentosa
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn